Global Meta-analysis of Urine Microbiome: Colonization of Polycyclic Aromatic Hydrocarbon-degrading Bacteria Among Bladder Cancer Patients.


Journal

European urology oncology
ISSN: 2588-9311
Titre abrégé: Eur Urol Oncol
Pays: Netherlands
ID NLM: 101724904

Informations de publication

Date de publication:
04 2023
Historique:
received: 11 11 2022
revised: 28 12 2022
accepted: 08 02 2023
medline: 18 4 2023
pubmed: 4 3 2023
entrez: 3 3 2023
Statut: ppublish

Résumé

The application of next-generation sequencing techniques has enabled characterization of urinary tract microbiome. Although many studies have demonstrated associations between the human microbiome and bladder cancer (BC), these have not always reported consistent results, thereby necessitating cross-study comparisons. Thus, the fundamental questions remain how we can utilize this knowledge. The aim of our study was to examine the disease-associated changes in urine microbiome communities globally utilizing a machine learning algorithm. Raw FASTQ files were downloaded for the three published studies in urinary microbiome in BC patients, in addition to our own prospectively collected cohort. Demultiplexing and classification were performed using the QIIME 2020.8 platform. De novo operational taxonomic units were clustered using the uCLUST algorithm and defined by 97% sequence similarity and classified at the phylum level against the Silva RNA sequence database. The metadata available from the three studies included were used to evaluate the differential abundance between BC patients and controls via a random-effect meta-analysis using the metagen R function. A machine learning analysis was performed using the SIAMCAT R package. Our study includes 129 BC urine and 60 healthy control samples across four different countries. We identified a total of 97/548 genera to be differentially abundant in the BC urine microbiome compared with that of healthy patients. Overall, while the differences in diversity metrics were clustered around the country of origin (Kruskal-Wallis, p < 0.001), collection methodology was a driver of microbiome composition. When assessing dataset from China, Hungary, and Croatia, data demonstrated no discrimination capacity to distinguish between BC patients and healthy adults (area under the curve [AUC] 0.577). However, inclusion of samples with catheterized urine improved the diagnostic accuracy of prediction for BC to AUC 0.995, with precision-recall AUC = 0.994. Through elimination of contaminants associated with the collection methodology among all cohorts, our study identified increased abundance of polycyclic aromatic hydrocarbon (PAH)-degrading bacteria Sphingomonas, Acinetobacter, Micrococcus, Pseudomonas, and Ralstonia to be consistently present in BC patients. The microbiota of the BC population may be a reflection of PAH exposure from smoking, environmental pollutants, and ingestion. Presence of PAHs in the urine of BC patients may allow for a unique metabolic niche and provide necessary metabolic resources where other bacteria are not able to flourish. Furthermore, we found that while compositional differences are associated with geography more than with disease, many are driven by the collection methodology. The goal of our study was to compare the urine microbiome of bladder cancer patients with that of healthy controls and evaluate any potential bacteria that may be more likely to be found in patients with bladder cancer. Our study is unique as it evaluates this across multiple countries, to find a common pattern. After we removed some of the contamination, we were able to localize several key bacteria that are more likely to be found in the urine of bladder cancer patients. These bacteria all share their ability to break down tobacco carcinogens.

Sections du résumé

BACKGROUND
The application of next-generation sequencing techniques has enabled characterization of urinary tract microbiome. Although many studies have demonstrated associations between the human microbiome and bladder cancer (BC), these have not always reported consistent results, thereby necessitating cross-study comparisons. Thus, the fundamental questions remain how we can utilize this knowledge.
OBJECTIVE
The aim of our study was to examine the disease-associated changes in urine microbiome communities globally utilizing a machine learning algorithm.
DESIGN, SETTING, AND PARTICIPANTS
Raw FASTQ files were downloaded for the three published studies in urinary microbiome in BC patients, in addition to our own prospectively collected cohort.
OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS
Demultiplexing and classification were performed using the QIIME 2020.8 platform. De novo operational taxonomic units were clustered using the uCLUST algorithm and defined by 97% sequence similarity and classified at the phylum level against the Silva RNA sequence database. The metadata available from the three studies included were used to evaluate the differential abundance between BC patients and controls via a random-effect meta-analysis using the metagen R function. A machine learning analysis was performed using the SIAMCAT R package.
RESULTS AND LIMITATIONS
Our study includes 129 BC urine and 60 healthy control samples across four different countries. We identified a total of 97/548 genera to be differentially abundant in the BC urine microbiome compared with that of healthy patients. Overall, while the differences in diversity metrics were clustered around the country of origin (Kruskal-Wallis, p < 0.001), collection methodology was a driver of microbiome composition. When assessing dataset from China, Hungary, and Croatia, data demonstrated no discrimination capacity to distinguish between BC patients and healthy adults (area under the curve [AUC] 0.577). However, inclusion of samples with catheterized urine improved the diagnostic accuracy of prediction for BC to AUC 0.995, with precision-recall AUC = 0.994. Through elimination of contaminants associated with the collection methodology among all cohorts, our study identified increased abundance of polycyclic aromatic hydrocarbon (PAH)-degrading bacteria Sphingomonas, Acinetobacter, Micrococcus, Pseudomonas, and Ralstonia to be consistently present in BC patients.
CONCLUSIONS
The microbiota of the BC population may be a reflection of PAH exposure from smoking, environmental pollutants, and ingestion. Presence of PAHs in the urine of BC patients may allow for a unique metabolic niche and provide necessary metabolic resources where other bacteria are not able to flourish. Furthermore, we found that while compositional differences are associated with geography more than with disease, many are driven by the collection methodology.
PATIENT SUMMARY
The goal of our study was to compare the urine microbiome of bladder cancer patients with that of healthy controls and evaluate any potential bacteria that may be more likely to be found in patients with bladder cancer. Our study is unique as it evaluates this across multiple countries, to find a common pattern. After we removed some of the contamination, we were able to localize several key bacteria that are more likely to be found in the urine of bladder cancer patients. These bacteria all share their ability to break down tobacco carcinogens.

Identifiants

pubmed: 36868921
pii: S2588-9311(23)00036-6
doi: 10.1016/j.euo.2023.02.004
pii:
doi:

Substances chimiques

RNA, Ribosomal, 16S 0

Types de publication

Meta-Analysis Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

190-203

Subventions

Organisme : NCI NIH HHS
ID : P30 CA043703
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA006927
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI145289
Pays : United States

Informations de copyright

Copyright © 2023 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Auteurs

Laura Bukavina (L)

Fox Chase Cancer Center, Philadelphia, PA, USA; University Hospitals Cleveland Medical Center, Cleveland, OH, USA; Case Western Reserve School of Medicine, Cleveland, OH, USA. Electronic address: Laura.Bukavina@FCCC.edu.

Ilaha Isali (I)

University Hospitals Cleveland Medical Center, Cleveland, OH, USA; Case Western Reserve School of Medicine, Cleveland, OH, USA.

Rashida Ginwala (R)

University Hospitals Cleveland Medical Center, Cleveland, OH, USA.

Mohit Sindhani (M)

India Institute of Technology, Delhi, India.

Adam Calaway (A)

University Hospitals Cleveland Medical Center, Cleveland, OH, USA; Case Western Reserve School of Medicine, Cleveland, OH, USA.

Diana Magee (D)

Fox Chase Cancer Center, Philadelphia, PA, USA.

Benjamin Miron (B)

Fox Chase Cancer Center, Philadelphia, PA, USA.

Andres Correa (A)

Fox Chase Cancer Center, Philadelphia, PA, USA.

Alexander Kutikov (A)

Fox Chase Cancer Center, Philadelphia, PA, USA.

Matthew Zibelman (M)

Fox Chase Cancer Center, Philadelphia, PA, USA.

Mahmoud Ghannoum (M)

University Hospitals Cleveland Medical Center, Cleveland, OH, USA; Case Western Reserve School of Medicine, Cleveland, OH, USA.

Mauricio Retuerto (M)

Case Western Reserve School of Medicine, Cleveland, OH, USA.

Lee Ponsky (L)

University Hospitals Cleveland Medical Center, Cleveland, OH, USA; Case Western Reserve School of Medicine, Cleveland, OH, USA.

Sarah Markt (S)

Case Western Reserve School of Medicine, Cleveland, OH, USA.

Robert Uzzo (R)

Fox Chase Cancer Center, Philadelphia, PA, USA.

Philip Abbosh (P)

Fox Chase Cancer Center, Philadelphia, PA, USA; Albert Einstein Medical Center, Philadelphia, PA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH